[144] Axsome Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Axsome Therapeutics, Inc. (AXSM) Form 144 notice reports a proposed sale of 10,000 common shares through Charles Schwab with an aggregate market value of $1,159,571, based on approximately 49,901,487 shares outstanding. The shares were acquired on 09/22/2025 through an employee stock option exercise and the payment method is listed as a broker payment for cashless exercise. The filing also discloses a prior sale by Mark L. Jacobson of 45,783 shares on 09/16/2025 generating $5,241,305 in gross proceeds. The filer affirms no undisclosed material adverse information and includes standard Rule 144 representations.

Insights

Financial Analyst

TL;DR: Insider exercised options and filed to sell 10,000 shares; a recent larger sale of 45,783 shares generated $5.24M in proceeds.

The filing documents a routine Rule 144 sale following an employee option exercise. The proposed 10,000-share sale equals an aggregate market value of $1.16M against total outstanding shares of ~49.9M, representing a small fraction of float. The prior sale by Mark L. Jacobson on 09/16/2025 for $5.24M is disclosed, indicating recent insider liquidity events. From a financial-materiality perspective these transactions are modest relative to share count and do not, by themselves, indicate a material change to capitalization or control.

Corporate Governance Expert

TL;DR: Filing appears procedurally correct under Rule 144 with standard representations about material nonpublic information.

The notice identifies the relationship to the issuer as an employee option exercise and specifies a cashless exercise processed via broker. The signer affirms the absence of undisclosed material adverse information and includes the required attestation language. The disclosure of a separate recent sale by an identified seller provides transparency on other recent insider dispositions. No governance red flags are evident from the form alone; it is a routine insider sale notice.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	10000	1159571.00	49901487	09/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/22/2025	Employee Stock Option Exercise	Axsome Therapeutics, Inc.			10000	09/22/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MARK L JACOBSON ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	09/16/2025	45783	5241305.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the AXSM Form 144 disclose about the proposed sale?

The Form 144 discloses a proposed sale of 10,000 common shares acquired by employee stock option exercise on 09/22/2025 with an aggregate market value of $1,159,571 via Charles Schwab.

Who executed a recent sale disclosed in the filing and how much were proceeds?

The filing shows that Mark L. Jacobson sold 45,783 shares on 09/16/2025 for gross proceeds of $5,241,305.

How many shares outstanding does Axsome report in this filing?

The Form 144 reports 49,901,487 shares outstanding for Axsome Therapeutics, Inc.

What was the acquisition and payment method for the 10,000 shares?

The shares were acquired on 09/22/2025 via an employee stock option exercise and the payment was a broker payment for cashless exercise.

Which broker is handling the proposed sale of AXSM shares?

The broker named in the Form 144 is Charles Schwab & Co., Inc. located at the address listed in the filing.